Knight Cancer and Response Genetics

In April the Knight Diagnostic Laboratories  at Oregon Health & Science University and Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced the execution of an exclusive commercial agreement for a proprietary next generation sequencing panel for lung cancer.  Read more here.